NFNana Feng

Nana Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nana Feng has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Zhang

    State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    4 shared publications
  • Qian Zhang

    Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    2 shared publications
  • Xing Yang

    School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    2 shared publications
  • Yue Liu

    State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    2 shared publications
  • Benyi Tan

    Tibet Rhodiola Pharmaceutical Holding Co., Lhasa 850000, China

    1 shared publication
  • Ce Tang

    State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    1 shared publication

Latest Publications

  • Open Access

    Dynamic Associations Among Sensory Characteristics, Alkaloid Profiles, and Cardiotoxicity Variation During Zanba Processing of Tibetan Medicine Tiebangchui

    by Qingya Yu, Ruichen Zhou, Benyi Tan, Jian Wu, Huanang Chen, Yuying Song, Nana Feng, Yan Zhang, Yue Liu, Yi Zhang

    Zanba stir-frying is a traditional processing method used to attenuate the toxicity of Tibetan medicine Tiebangchui (TBC; Aconitum pendulum Busch). This study examined associations among electronic sensory measurements, targeted alkaloid profiles, and cardiac injury endpoints across processing times. Liquid chromatography–triple-quadrupole tandem mass spectrometry (LC-QQQ-MS/MS) was used to determine aconitine, 3-deoxyaconitine, benzoylaconine, aconine, neoline, 12-epi-napelline, and 16-epi-pyroaconitine. Colorimetric measurements showed an overall decrease in lightness and an increase in color difference relative to raw TBC. Electronic-nose responses varied with processing time and sensor, but no uniform monotonic trend was found; bitterness responses showed comparatively minimal changes. The sum of the two measured diester-diterpenoid alkaloids, aconitine and 3-deoxyaconitine, decreased from 159.21 μg/g in raw TBC to 6.50 μg/g at 60 min. Benzoylaconine level increased initially and subsequently decreased; 12-epi-napelline and the pyro-type alkaloid 16-epi-pyroaconitine were evaluated separately. In rats, processed TBC produced lower cardiac injury markers and higher myocardial ATP and ATPase endpoints compared with raw TBC. The changes observed at approximately 60 min support further assessment of this processing interval. These findings link processing-associated changes in sensory characteristics and alkaloid profiles with changes in cardiac injury and myocardial energy-related endpoints, providing a basis for the further development of quantitative approaches to evaluating the Zanba processing of Tiebangchui.

  • Open Access

    Bitter Compounds in Medicinal Food Plants Based on Traditional Chinese Medicine: Analysis and Regulation Strategies from Chemical Structure to Perception Mechanisms

    by Yuanyuan Li, Nana Feng, Di Yang, Qian Zhang, Xinyan Zhao, Xing Yang, Qingya Yu, Zhaotong Cong, Tingting Kuang, Ce Tang, et al.

    Bitter phytochemicals, including alkaloids, terpenoids, and bitter glycosides, are abundant in medicinal food plants and exhibit well-documented anti-inflammatory, hypoglycemic, and other bioactivities relevant to human health. However, the inherent bitterness of these compounds presents a significant sensory barrier to patient compliance and limits their application as functional food ingredients. This review provides a comprehensive and interdisciplinary synthesis of current knowledge on bitter compounds in medicinal food plants, integrating perspectives from phytochemistry, molecular pharmacology, and sensory science. We summarize the major chemical classes of bitter phytochemicals, critically evaluate methods for their isolation and identification—from classical sensory-guided fractionation to modern computational approaches such as molecular docking and metabolomics—and analyze three principal strategies for bitterness regulation: physical removal, biological transformation, and sensory modulation (including molecular inclusion and TAS2R receptor blocking). We also briefly touch upon the extraoral expression of TAS2Rs and there suggested links to local immune responses and metabolic regulation, noting that this may be relevant to the concept of “taste–bioactivity homology.” The review further highlights ongoing challenges, such as the identification of unknown bitter compounds and the lack of standardized sensory evaluation systems, and outlines possible directions for improving bitterness analysis and regulation in medicinal food plants.


  • Open Access

    12-epi-Turpelline, a Novel C20 Diterpene Alkaloid Isolated from Zanba Stir-Fried Tiebangchui

    by Siqi He, Lei Yang, Shilong Meng, Nana Feng, Yue Liu, Yi Zhang, Donglin Chen

    Aconitum pendulum Busch (Tiebangchui), a traditional Chinese medicinal herb, is recognized for its diverse pharmacological properties and for its significant toxicity. The Zanba stir-frying processing method is commonly employed to mitigate toxicity and enhance efficacy; however, the underlying chemical principles remain insufficiently studied. In order to address this issue, a phytochemical investigation was conducted on the diterpenoid alkaloids present in Zanba-processed Tiebangchui. Eleven diterpenoid alkaloids were isolated by means of chromatographic techniques, including silica gel column chromatography. Their structures were elucidated by extensive spectroscopic analysis (single-crystal X-ray diffraction, IR, HR-ESI-MS) and comparison with literature data. The compounds were identified as 12-epi-turpelline (1), 12-epi-napelline (2), 12-acetyl-napelline (3), azitine (4), flavaconitine (5), nagarutine C (6), nagarutine D (7), 16-epi-pyroaconine (8), spicatine B (9), 3-deoxyaconitine (10), and napelline (11). Notably, compound 1 was characterized as a novel alkaloid. Additionally, compounds 3–9 were isolated from this processed material for the first time. These findings provide crucial chemical insights into the detoxification mechanism of Zanba processing. Subsequent pharmacological evaluation revealed that compounds 10 and 11 exhibit notable anti-inflammatory activities. Moreover, given the structural analogy between the novel alkaloid 1 and the active compound 11, compound 1 is proposed as a promising lead for future structure–activity relationship studies and semi-synthetic modification.

  • Open Access

    Unlocking Mangiferin: A Therapeutic Candidate Revolutionizing Liver Disease Therapy

    by Jihang Xie, Sijing Su, Jianfa Wu, Xing Yang, Qian Zhang, Xiaojiang Shen, Linlin Zhao, Ting Wang, Nana Feng, Jinsong Su, et al.

    Mangiferin (MF), a natural component widely found in fruits, vegetables, and herbs, has garnered increasing attention for its potent antioxidative properties and therapeutic potential. This bioactive xanthone compound plays a crucial role in mitigating oxidative stress, which is a key factor in the pathogenesis of various diseases, including liver diseases. As a powerful natural antioxidant, MF exhibits a wide range of hepatoprotective effects, making it a promising candidate for liver disease therapy. In this review, we systematically examine the source and chemical properties, synthetic pathways, pharmacokinetic characteristics, and bioavailability enhancement strategies of MF. Furthermore, we explore its mechanisms of action in treating liver diseases, with a focus on its antioxidative properties and their role in modulating liver disease progression. Given the growing burden of liver disease and the limitations of current therapies, this review aims to promote the clinical application of MF as a therapeutic candidate, paving the way for innovative therapeutic strategies for liver diseases.